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Abstract:  Parkinson’s disease (PD) is the second most common progressive 
neurodegenerative disorder after Alzheimer's disease (AD) and represents a large health 
burden to society. Genetic and oxidative risk factors have been proposed as possible 
causes, but their relative contribution remains unclear. Dysfunction of alpha-synuclein (α-
syn) has been associated with PD due to its increased presence, together with iron, in Lewy 
bodies. Brain oxidative damage caused by iron may be partly mediated by α-syn 
oligomerization during PD pathology. Also, α-syn gene dosage can cause familial PD and 
inhibition of its gene expression by blocking translation via a newly identified Iron 
Responsive Element-like RNA sequence in its 5’-untranslated region may provide a new 
PD drug target. 
 
Keywords:  PD: Parkinson's disease; AD: Alzheimer's disease; α-syn: alpha-synuclein; 
PLD2: phospholipase D2; CNS: central nervous system; ER: endoplasmatic reticulum; 
PM: plasmatic membrane; LBs: Lewy bodies; LNs: Lewy neurites; GCIs: glial cytoplasmic 
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inclusions; DLB: dementia with Lewy Bodies; DA: dopamine; DAT: dopamine 
transporter; NAC: non-amyloidogenic component; 5-UTR: 5'-untranslated region; IRE: 
iron responsive element; IRPs: interacting binding proteins; wt: wild-type; ROS: reactive 
oxygen species; GSH: reduced gluthatione; 6-OHDA: 6-hydroxydopamine; MPTP: 1-
methyl 4-phenyl 1, 2, 3, 6 tetrapyridine; TfR: transferrin receptor; TH: tyrosine 
hydroxylase; nt: nucleotide(s); aa: amino acid(s). 
 
1. Parkinson’s Disease: Clinical Profile, Pathophysiology and Treatments  
 
1.1. Clinical profile 
 
PD is a progressive neurodegenerative disorder that affects approximately 1% of the population 
beyond 65 years old [1]. A study of mortality among PD patients showed an odds ratio of 2.5 
compared with age-matched subjects [2]. The diagnosis of PD continues to be based on presenting 
signs and symptoms. Dyskinesia is the most obvious clinical symptom and often starts in one 
extremity and worsens with stress, fatigue and cold. Bradykinesia is usually the most troublesome 
symptom. Patients refer to slowness in performing their daily activities. Rigidity of muscles on passive 
movement, including joints, is also a characteristic of PD [3].  
 
1.2. Pathophysiology 
 
The primary brain abnormality found in all patients is a degeneration of nigrostratial dopaminergic 
neurons in the substantia nigra, which leads to the depletion of dopamine (DA) with consequent loss 
of neuronal systems responsible of motor functions, and the formation of intracytoplasmic inclusions 
called Lewy bodies (LBs) in remaining neurons [4]. 
It is thought that the cause of idiopathic PD may be an interaction of environmental and genetic 
factors [4]. More typically, PD is sporadic when there is no family history of disease although a study 
has suggested a significant contribution of heredability to the development of late-onset PD [5]. In 
pedigrees with autosomal-recessive early-onset parkinsonism, a wide variety of mutations to the parkin 
gene (Park-2 gene) were found in families in which at least one member developed the symptoms [6]. 
Also, a number of hereditable genetic autosomal-dominant mutations have been found in the α-syn 
gene (also known as SNCA), besides other genes, as rare cause of PD, helping in understanding the 
disease [5]. α-syn has received much attention because it is the major component of LBs. In addition, 
α-syn pathologies accumulate throughout the central nervous system (CNS) in areas that also undergo 
progressive neurodegeneration, leading to dementia and other behavioural impairments as well as 
parkinsonism [7]. 
 
1.3. Treatments (see Table 1) 
 
Although significant advances have been made in understanding the pathophysiology of this 
disease, there is no curative treatment and only symptoms can be controlled. The management of PD is Int. J. Mol. Sci. 2009, 10                 
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designed to improve the patient’s quality of life. Symptomatic therapy is based totally on the 
requirements of the individual patient and must be re-evaluated as the condition evolves. 
Neuroprotective therapy is currently unavailable, in spite of the initial promising data from the 
DATATOP study performed with the monoamino oxidase (MAO) inhibitor selegiline, definitive 
neuroprotective action has yet to be demonstrated and its actions can be off set by its side effects that 
may include nausea, dizziness, insomnia and cognitive impairment. Actually, the American Academy 
of Neurology suggests that there is currently insufficient evidence to recommend selegiline as a 
neuroprotective treatment [8]. 
L-Dopa is presently the most efficacious treatment for PD [9]. L-dopa is converted into DA within 
the nigrostratial neurons by the enzyme aromatic L-amino acid decaboxylase. This enzyme is a rate-
limiting in DA synthesis in PD, but not in healthy individuals, and pyridoxal phosphate (vitamin B6) is 
a required cofactor for the decarboxylation which may be administered together with L-dopa as 
pyridoxine. Conversion of L-dopa to DA likewise occurs systemically, outside the brain, in peripheral 
tissues, and thereby may induce adverse effects. It is hence standard clinical practice to co-administer a 
peripheral DOPA decarboxylase inhibitor that is restricted from entering brain, such as carbidopa or 
benserazide, and often a catechol-O-methyl transferase (COMT) inhibitor, to prevent peripheral tissue 
synthesis of DA. Essentially, all patients require L-dopa at some stage of the disease. However, careful 
L-dopa titration is essential since it may induce dyskinesias and other L-dopa side effects. The most 
common is the “wearing-off” phenomenon or shortening of sustainable pharmacological action. This 
occurs when the symptoms of PD, attenuated by the treatment, become more intense before the next 
dose. The response usually is an increase of L-dopa dose frequency and addition of alternative 
therapies, such as the COMT inhibitor entacapone, DA agonists, amantadine or selegiline [10] (see 
below). The major inconvenience of L-dopa is dyskinesias or involuntary movements related to the 
drug. The addition of amantadine usually attenuates dyskinesias [11]. Although L-dopa is associated 
with motor complications, it must be acknowledged that survival has been considerably prolonged in 
PD since its introduction. Moreover, as in healthy animals, individuals misdiagnosed with PD and 
exposed to long-term L-dopa treatment did not show signs of parkinsonism [12,13]. 
In specific clinical situations, lower potency drugs are used. As listed in Table 1, anticholinergics 
(benztropine, biperiden, diphenhydramine, ethopropazine, orphenadrine, procyclidine and 
trihexyphenidyl) provide mild symptomatic treatment and may be beneficial to treat tremors [14]. 
Unfortunately, many patients experience cognitive change following anticholinergics, and therefore 
they are generally restricted to younger patients. Amantadine, a N-methyl-D-aspartate receptor 
antagonist, also provides mild symptomatic benefit in early stages of disease. This agent is relatively 
inexpensive, with a low incidence of adverse effects but is also associated with confusion in older 
patients [10]. DA agonists (mainly bromocriptine, pramipexole, ropinerole and pergolide) directly 
stimulate DA receptors and do not need to be metabolized into an active drug. They may hence have 
potential advantages over L-dopa by having a longer half-life, a longer duration of symptomatic action 
and, most importantly, DA agonists are rarely associated with motor fluctuations and dyskinesias [15]. 
Nevertheless, patients may succumb to other side effects, such as hallucinations, hypotension, anxiety, 
depression, bladder dysfunction, insomnia, edema and cognitive impairment. 
Several clinical trials have shown a decrease of dystonia and dyskinesia, and a similar clinical 
benefit when patients with early stage PD were treated with the DA receptor agonist bromocriptine, or Int. J. Mol. Sci. 2009, 10                 
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Class drug    Mechanism of action    Side effects          Specific drug 
Anticholinergics   Block acetylcholine    Dry mouth, dry eyes,       Trihexyphenidy 
receptors   urinary  retention,    Benztropine 
          exacerbation  of glaucoma,   Ethopropazine 
       cognitive  impairment 
 
 
Amantadine    Blocks NMDA and     Cognitive dysfunction,           Amantadine 
acetylcholine receptors     peripheral edema and  
and promotes release of DA  skin rash 
 
 
L-dopa      Metabolism to DA in cells    Nausea, hypotension,             L-dopa/carbidopa 
      containing dopa-decarboxylase  hallucinations, psychosis,            Sinemet CR 
              dystonic and                             L-dopa/benserazide 
choreiform dyskinesias 
 
DA agonists    Stimulate DA receptors    Nausea, hypotension,         Bromocriptine 
       hallucinations,  psychosis              Pergolide 
       peripheral  edema,                  Ropinirole 
       pulmonary  fibrosis,                  Pramipexole 
insomnia 
 
MAO inhibitors    Block MAO-B receptors    Nausea, dizziness,           Selegiline 
      to reduce DA metabolism   sleep disorder and       
impaired cognition 
 
Catechol O-    Block peripheral COMT    L-dopa related side-effect          Entacapone 
(COMT) inhibitors   Methyltranferase     activity    exacerbation,       Tolcapone 
to improve L-dopa     diarrhea, urine discoloration   
 pharmacokinetics     
L-dopa alone [16]. A similar result was obtained by using ropinirole plus L-dopa, if required [17]. 
These data support the use of DA agonists in early PD together smaller doses of L-dopa to minimize 
complications related to the latter [15]. In addition, several in vitro and animal studies might indicate a 
role for neuroprotection for DA agonists [18-21], although clinical benefit in humans is to prove. Other 
DA agonists, apomorphine, lisuride and carbegoline are also available, however, the choice of one 
them taking into account their effectiveness and/or non-motor symptoms remains unclear. 
In addition, COMT is a selective and widely distributed enzyme involved in the catabolism of L-
dopa. Tolcapone and entacapone are selective and potent COMT inhibitors that slow the metabolism of 
L-dopa, thus prolonging its effects [22]. Tolcapone has been shown to be an effective adjunct in the 
treatment of PD in Phase II and III clinical trials, improving motor fluctuations and reducing L-dopa 
requirements. Rare reports of severe hepatotoxicity, however, have limited tolcapone implementation 
in the treatment of PD [23]. 
 
Table 1. Drugs used to treat Parkinson’s disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The currently available therapies for PD, as in Table 1, are symptomatic and become less effective 
over time. Therefore, in order to identify potential neuroprotective agents available for testing, the 
Committee to Identify Neuroprotective Agents in Parkinson's (CINAPS), supported by the National 
Institute of Neurologic Disorders and Stroke (NINDS), conducted a systematic assessment of presently Int. J. Mol. Sci. 2009, 10                 
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available pharmacologic agents. From a list of 59 potential neuroprotective agents, the Committee 
identified 12 agents that are currently available and should be considered priority agents for further 
investigation in PD [24] (see Table 2, which includes neuroprective agents). 
 
Table 2. Drugs accepted by CINAPS. 
Agent Mechanism  Comments 
Caffeine  Adenosine antagonist  KW-6002, a specific A2A receptor antagonist in development 
Coenzyme Q10 
Antioxidant / 
mitochondrial stabilizer 
Dietary supplement; modest symptomatic benefit based on phase 2 studies 
Creatine 
Mitochondrial 
stabilizer 
Dietary supplement 
Estrogen (17 beta-
estradiol) 
Undetermined    
GM-1 ganglioside  Trophic factor    
GPI-1485 Trophic  factor  Neuroimmunophilin ligand 
Minocycline 
Anti-inflammatory / 
anti-apoptotic 
Antibiotic 
Nicotine Undetermined     
Pramipexole Antioxidant 
Dopamine agonist; clinical neuroimaging data demonstrate a possible disease-
modifying effect; exact interpretation and clinical meaning of data remain 
unclear 
Rasagiline 
Antioxidant / anti-
apoptotic 
Selective MAO-B inhibitor; symptomatic benefit in early- and advanced-stage 
PD based on several phase 3 studies 
Ropinirole Antioxidant 
Dopamine agonist; clinical neuroimaging data demonstrate a possible disease-
modifying effect; exact interpretation and clinical meaning of data remain 
unclear 
Selegiline 
Antioxidant / anti-
apoptotic 
Selective MAO-B inhibitor; DATATOP study failed to demonstrate 
neuroprotective benefits 
 
2. alpha-Synuclein: Relationship with PD. Biochemical and Biological Properties 
 
2.1. Relationship with PD 
 
As mentioned above, PD neurodegeneration is accompanied by the presence of LBs and Lewy 
neuritic inclusions (LNs) in surviving dopaminergic neurons [25], in which the main component 
derives from fibrillar aggregates of α-syn [26,27], although α-syn inclusions are also found in non-Int. J. Mol. Sci. 2009, 10                 
 
 
1231
dopaminergic neurons (called neuronal cytoplasmic inclusions), in glial cells (glial cytoplasmic 
inclusions, GCIs) and as axonal spheroids [28].  
The main evidence of the relevant role of α-syn in PD came from the discovery of three point 
mutations in the α-syn gene that can cause hereditable early-onset PD [29] in rare pedigrees. These 
mutations are A53T (change Ala in position 53 to Thr) [30], A30P (change Ala in position 30 to Pro) 
[31] and E46K (change Glu in position 46 to Lys) [32]. All three occur within the N-terminal side of 
the protein and are able to accelerate the α-syn  oligomeric aggregation process and protofibril 
formation [33] faster than wild-type (wt) α-syn. Therefore, the insoluble fibrillization rate was also 
higher (with the exception of the A30P mutation) than in wt variant [34,35], leading to pathologic 
inclusions, such as LBs and LNs. 
Interestingly, several clinical features may be distinguished among A53T carriers vs. idiopathic PD 
patients, such as a slightly earlier onset, a faster disease progression, a lower tremor prevalence, and 
dementia [36]. By contrast, patients with the A30P mutation resemble idiopathic PD. The E46K 
patients exhibit dementia with Lewy Bodies (DLB) and hallucinations, as well as parkinsonism. This 
mutation, which substitutes a dicarboxylic amino acid, glutamic acid, with a basic amino acid such as 
lysine in a much conserved area of the protein, is likely to produce a severe disturbance of protein 
function [32]. On the other hand, genetic polymorphisms in the α-syn gene appear to confer risk for 
sporadic PD [37]. In fact, in the Japanese population there are several polymorphisms in the intron 1 
that may be associated with PD [38]. Furthermore, duplication or triplication of the α-syn gene has 
been reported in familial forms of PD [39], and could implicate gene dosage effects in the PD 
pathogenesis [40]. 
In agreement with genetic and clinical findings, transgenic animal models have revealed an 
association between α-syn and the disease. In Drosophila, for example, when wt- α-syn, A30P or 
A53T mutants are overexpressed, a motor dysfunction, selective loss of DA neurons and presence of 
filamentous intraneuronal inclusions that contain α-syn occur [41]. In contrast, α-syn knock-out mice 
possess an abnormal activity of DA neurons with reduced levels of DA detected in the striatum. This 
implies that the protein may play a role in the regulation of neurotransmitter release [42]. 
The importance of the link between α-syn and PD, together with the discovery of detectable levels 
of α-syn in CSF and in human plasma, suggesting that α-syn is released from affected dopaminergic 
neurons [43], indicates that α-syn could serve as a marker for early diagnosis of PD. In this regard, an 
Enzyme-Linked Immuno Sorbent Assay (ELISA) based method has recently been developed to detect 
oligomeric  α-syn in CSF and plasma and could serve as a diagnostic tool for PD and related   
diseases [44]. 
 
2.2. Biochemical and biological properties 
 
α-Syn belongs to the synuclein family, which includes β-syn and γ-syn [45]. α-syn and β-syn are 
predominantly expressed in brain at presynaptic terminals, particularly in the neocortex, hippocampus, 
striatum, thalamus and cerebellum [46,47]. γ-syn is highly expressed in several areas in the brain, 
particularly in the substantia nigra, and has been found to be overexpressed in some breast and ovarian 
tumors [48]. α-syn homologues have been found in several mammals, but not in lower organisms such 
as Escherichia coli, yeasts, Drosophila or Caenorhabditis elegans. Int. J. Mol. Sci. 2009, 10                 
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α-Syn is a small protein (14 kDa) composed of 140 aminoacids (aa). It is a soluble, acidic, resistant 
to high temperatures and natively unfolded protein with an extended structure that is mainly composed 
of random coils [49]. However, it acquires secondary structure elements upon interaction with ligands 
and proteins, adopting a partially folded conformation [50]. A report suggests that unfolded states play 
a functional role in vesicle fusion in all eukaryotics, bringing membrane surfaces to facilitate fusion, 
and, after binding, an ordered structure is acquired [51].  
The  α-syn sequence can be subdivided in three domains (Figure 1). The highly conserved N-
terminal domain (residues 1-65) is unordered in solution and includes seven copies of an unusual 11 aa 
repeat that displays variations of a KTKEGV consensus sequence that may shift to an α-helical 
structure under certain conditions [52,53]. α-syn can interact with synthetic phospholipid vesicles 
through this domain [54], suggesting that the protein may be membrane-associated [55], becoming α-
helix conformation after binding [56]. 
Figure 1. Alpha-synuclein’s sequence and domains. Blue highlighted: four α-helices 
responsible for protein-membrane interactions. Red highlighted: NAC or non-Aβ 
(amyloidogenic) component of α-syn, responsible of protein-protein interactions. Yellow 
highlighted: the unstructured C-terminal domain. Exons that undergo alternative splicing 
are indicated in bold: exon 3 from codon 41 to 54 and exon 5 from codon 103 to 130. 
Mutations A30P, E46K and A53T are in bold and enhanced. The seven 11 aa repeats are 
shown between the square brackets. 
        30     46                53  
MDVFMKGL[SKAKEGVVAAA] [EKTKQGVAEAA] [GKTKEGVLYVG] [SKTKEGVVHGV]ATVA[EKTK 
 
EQVTNVG] [GAVVTGVTAVA] [QKTVEGAGSIA]AATGFVKKDQLGKNEEGAPQEGILEDMPVDPDNEAY 
 
EMPSEEGYQDYEPEA 
 
The A53T and A30P mutations do not affect the overall structure of α-syn, which remains unfolded, 
but diminish hydrophobicity of the N-terminal domain; thereby somewhat reducing its ability to form 
α-helices. The predisposition to form β-sheet structures is enhanced [50], which renders it more prone 
to aggregation. Whereas A53T does not affect vesicle binding, A30P is characterized by a decrease in 
lipid binding [33]. 
The central hydrophobic domain of α-syn (residues 66-95) is known as NAC. This peptide portion 
has been implicated in AD pathogenesis and is the second major component of brain AD amyloid 
plaques [57]. It is responsible for protein-protein interactions and confers on α-syn the ability to 
undergo a conformational change from a random coil to an aggregation-prone β-sheet structure [58] 
leading to the formation of amyloid-like fibrils [59]. An in vitro study demonstrated that aged NAC, 
dissolved in solution for seven days, is more toxic than fresh NAC, suggesting that cytotoxicity 
depends on prior aggregation [60]. The NAC region also contains a phosphorylation site on Ser-87. 
The acidic Glu-rich C-terminal domain (residues 96-140) has no recognized structure and a strong 
negative charge [52]. Several phosphorylation sites have been identified within this region, on Tyr-Int. J. Mol. Sci. 2009, 10                 
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125, -133 and -136, and Ser-129 [61]. Its acidic domain (aa 125-140) appears to be critical for the 
chaperone activity of α-syn [62]. Chaperones are proteins that prevent irreversible protein aggregation 
and facilitate the correct folding of proteins through binding in vivo. α-syn shares a 40% homology 
with a chaperone called 14-3-3 [63], suggesting that both proteins may share the same function. 
Chaperone 14-3-3 is particularly abundant in brain and can prevent apoptosis by binding with the pro-
apoptotic protein, BAD [64]. α-Syn selectively interacts with 14-3-3 in substantia nigra, where it 
accumulates in LBs, leading to a decrease in available levels of 14-3-3 to inhibit apoptosis [65]. Both 
α-syn and 14-3-3 interact with tyrosine hydroxylase (TH), the rate-limiting enzyme in catecholamine 
synthesis that is responsible for catalyzing the conversion of the amino acid L-tyrosine to L-dopa. TH 
activity is stimulated by 14-3-3 and inhibited by α-syn [66]. 
 
2.2.1. Posttranslational modifications 
 
All posttranslational modifications of proteins result in a change of protein size, structure or charge, 
leading to alterations of their original properties [67]. With regard to α-syn, there are several 
modifications: 
 
2.2.1.1. Phosphorylation 
 
Ser-129 was established as a major phosphorylation site, while another was identified at Ser-87. 
Casein kinases, CK1 and CK2, were found to be responsible for α-syn phosphorylation at Ser-129 and, 
probably, at Ser-87. Both are localized in the synaptosome and also phosphorylate other synaptic 
vesicle proteins [68]. In addition, the G-protein-coupled receptor kinases can phosphorylate α-syn [69].  
It has been determined that more than 90% of insoluble α-syn in LBs is phosphorylated. By 
contrast, phosphorylation involves only about 4% of normal α-syn, suggesting that phosphorylation is 
a relevant pathogenic event [70,71]. In this regard, phosphorylation at Ser-129 increases fibril 
formation [71]. 
Interestingly, cotransfection experiments of α-syn and synphilin-1, a protein that interacts with α-
syn, yielded cytoplasmic inclusions that were similar to LBs. Subsequent coexpression of S129A α-syn 
(that is unable to be phosphorylated at Ser-129), synphilin-1 and parkin (a ubiquitin ligase responsible 
for α-syn and synphilin-1 ubiquitination), showed an important decrease in cytoplasmic inclusions 
[72], indicating that phosphorylation at Ser-129 enhances the formation of inclusion bodies and is a 
necessary step in the development of LBs. Transgenic mouse models that overexpress α-syn have 
shown a neurodegeneration that is accompanied by phosphorylation at Ser-129, caspase 9 activation 
and apoptosis [73]. 
 
2.2.1.2. Nitration 
 
Nitration has been proposed as one of the oxidative mechanisms responsible of the formation of α-
syn oligomers, through di-tyrosine crosslinking [74]. Soluble nitrated α-syn is not efficiently processed 
by proteases, leading to partial folding, accumulation and fibril formation [75]. Consequently, nitrated 
α-syn has been found in LBs deriving from brains with PD [76]. The primary sequence of α-syn Int. J. Mol. Sci. 2009, 10                 
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contains four sites for potential nitration: Tyr-39, -125, -133 and -136, all of which have been found 
nitrated in LBs [77]. 
 
2.2.1.3. Ubiquitination 
 
Protein modification by ubiquitin is one of the main mechanisms of protein targeting for 
proteasome degradation. Specifically regarding α-syn, the specific substrate for ubiquitination by 
parkin is the O-glycosylated α-syn form, with glycosylation potentially occurring at Ser-129 [78]. α-
Syn ubiquitination occurs in vivo at Lys-6, -10 and -12. Nevertheless, it remains unclear whether 
monomeric α-syn requires ubiquitination, since α-syn is a natively unfolded protein and, therefore, it 
may not require ubiquitination and unfolding. Instead, it could enter the 20S proteasome directly [67]. 
In contrast, ubiquitin moieties are present in LBs associated with α-syn aggregates [79]. In addition, 
only high molecular weight α-syn fibrils, and not the monomeric protein, are substrates for 
oligoubiquitination in sporadic LB diseases [80]. It thus appears that ubiquitination of α-syn is a 
pathologic event associated with LB formation. Moreover, α-syn and parkin colocalize together in 
LBs, and a report suggests that α-syn aggregation could precede ubiquitination [81]. 
Several mutations associated to early-onset PD have been described in genes related to 
ubiquitination, for example, within the ubiquitin C-terminal hydrolase gene [82], thereby highlighting 
the importance of the misfunction of this mechanism in parkinsonism.  
Protein degradation is tightly regulated in eukaryotic cells, and unfolded proteins, like α-syn, have a 
reduced lifetime and undergo a fast turnover. In many cases, this turnover is mediated by sequences 
rich in Pro, Glu, Ser and Thr, which target the protein for proteolysis [83], and are often present within 
a highly charged and unstructured region, preferentially in the C-terminal domain. 
 
2.2.2.  α-Synuclein alternative splicing 
 
Alternative splicing is a mechanism to support the generation of multiple mRNAs from a single 
transcript. Each alternatively spliced transcript contains significant changes in protein secondary 
structure that may cause functional alterations, and shifts the protein isoform ratio. There are two types 
of transcripts from pre-mRNA alternative splicing: C-terminal truncated proteins generated by reading 
frame changes that result in the introduction of a premature stop codon, and in-frame deletions with 
exon loss without a frame shift. With regard to α-syn, the 140 aa isoform is the whole protein and also 
the major transcript, whereas alternative splicing of exons 3 or 5 gives rise to 126 or 112 aa isoforms, 
respectively, both from in-frame deletions [67]. In addition, a 98 aa isoform of α-syn, which lacks 
exons 3 and 5, has been recently reported [84]. The splice-out of exon 3 results in the interruption of 
the helical protein-membrane interacting domain by deleting most of helix 3 and part of helix 4, and 
thereby impairing the aggregation-prone interaction with membranes [85]. Interestingly, the E46K and 
A53T mutations are sited in exon 3. 
α-Syn 112 lacks exon 5 (aa 103-130) located on the C-terminal half of the protein. It shows an 
enhanced tendency to aggregate and fibrillize [86], in spite of the lack of the main phosphorylation site 
located at Ser-129 (although maintaining the phosphorylation site at Ser-87). Thus, either 
phosphorylation or structural alterations are responsible for aggregation, but other explanations arise, Int. J. Mol. Sci. 2009, 10                 
 
 
1235
such as the lack of the proteolysis signal sequence at the C-terminus, leading to accumulation and 
aggregation. In addition, it has been proposed that the C-terminus may act as an intramolecular 
chaperone, preventing α-syn fibrillization [62]. 
A differential mRNA expression study [87] revealed different α-syn expression levels when 
comparing patients with DLB to controls. α-syn 140 expression levels were diminished as result of 
neuronal loss and an important 5-fold decrease of α-syn 126, together with a two-fold increase of α-syn 
112 and α-syn 98 were described [84], suggesting an involvement of these latter isoforms in DLB 
pathologies that likely related to LBs formation. The decrease in α-syn 126 expression probably 
unbalances the ratio among the three isoforms towards the more prone to aggregate 112 aa isoform, 
albeit that no pathological processes related to α-syn 126 have yet been reported. 
 
2.2.3. Vesicle trafficking regulation 
 
α-syn has the ability to bind phospholipid vesicles through its N-terminal domain, with four 
amphipathic α-helices that are typical of lipid-binding proteins. It is found in pre-synaptic termini, in 
equilibrium between free and membrane-bound states [88], with approximately 15% of α-syn being 
membrane-bound [55]. This led to the hypothesis that α-syn might regulate vesicular release and/or 
turnover and other synaptic functions within the CNS [59]. Expression profiling in transgenic flies 
revealed that expression of lipid and membrane transport genes were associated with α-syn expression 
[89]. Furthermore, overexpression of α-syn was accompanied by noticeable changes in membrane 
fluidity and in fatty acid uptake and metabolism [90]. 
An analysis of a yeast PD model revealed that the earliest defects following α-syn overexpression 
were an inhibition of the endoplasmatic reticulum (ER) to Golgi vesicular trafficking and an 
impairment of the ER-associated degradation [91]. In PC12 cells, α-syn regulates catecholamine 
release from synaptic vesicles, and its overexpression inhibits the vesicle priming process after 
secretory vesicle trafficking to docking sites [92]. Finally, α-syn appears also to be involved in the 
regulation of certain enzymes, transporters and neurotransmitter vesicles [93]. 
 
2.2.4. Interaction  with other proteins 
 
α-Syn acts as a specific inhibitor of phospholipase D2 (PLD2) [94], which hydrolyzes 
phosphatidylcholine to phosphatidic acid (PA) [95]. Activation of PLD2 and generation of PA elicits a 
wide array of cell responses, including Ca
2+ mobilization, secretion, superoxide production, 
endocytosis, exocytosis, vesicle trafficking, recycling of membrane receptors, transport to Golgi, 
rearrangements of cytoskeleton, mitogenesis and cell survival. PA can serve as a protein attachment 
site, altering membrane curvature and vesicle fusion [94]. 
Phosphorylation of α-syn by G-protein coupled receptor kinases results in a significant reduction in 
the α-syn affinity for phospholipids and a decrease in its binding with PLD2. Once detached from the 
plasmatic membrane (PM), α-syn is able to release any membrane-bound PLD2, allowing potential 
hydrolysis of phosphatidilcholine, the major lipidic component of cell membranes, to potentially 
increase membrane permeability [4]. 
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2.2.5. Chaperone  activity 
 
As discussed, α-syn has chaperone functions, assisting in the folding and unfolding of many 
synaptic proteins. In addition, transgenic mice with the cysteine-string protein-α (CSPα, a synaptic 
vesicle protein that acts as a co-chaperone) gene deleted have a phenotype of neurodegeneration. 
However, transgenic expression of α-syn prevented the development of this pathological sign. Thus, α-
syn appears to complement the chaperone activity of CSPα [96]. 
 
3. Pathogenic Mechanisms of Alpha-Synuclein. Factors Affecting Fibrillization. Role of Iron in 
Oxidative Stress 
 
3.1. Conformational states of α-synuclein 
 
The structural disposition of α-syn can show under a number of different conformations: 
(1)  The intrinsic unfolded state under physiologic conditions, both in vitro and in vivo. 
(2)  The pre-molten globule state, a compact but incompletely folded state of proteins that 
contains most of the secondary structure but lacks tertiary interactions [97], and is 
predominant under conditions such as low pH, high temperature, several metal ions [98], 
several salts [98], and several common pesticides/herbicides [99]. It is stabilized as result of 
spontaneous oligomerization both in vivo and in vitro [100]. It is thought that the negative 
electrostatical potential and locally low pH in the vicinity of the membrane surface induces 
protein conformation to molten globules. Early stages of fibrillization involve the partial 
folding of α-syn into the highly fibrillization-prone pre-molten globule conformation, which 
represents a key intermediate along the fibrillization pathway [101]. 
(3) The  α-helical membrane-bound form in the N-terminal fragment, while the glutamate-rich C-
terminal region remains unstructured. 
(4) The  β-sheet state: it has been observed that under certain conditions α-syn acquires a β-
pleated sheet, which is very prone to form amorphous aggregates [102]. 
(5) Dimers:  α-syn is able to form morphologically distinct oligomers, for example under high 
temperature [100], where dimers are formed first, and aggregates. The formation of oxidative 
dimers and high-order oligomers with covalent di-tyrosine cross-links under conditions of 
oxidative stress has also been reported [74]. 
(6) Oligomers:  nitrated  α-syn assembles into spherical oligomers [100]. Incubation of α-syn with 
several metals gave rise to different classes of oligomers: Cu
2+, Fe
3+ and Ni
2+ yielded 0.8-4 
nm spherical particles, similar to those formed by incubation of α-syn alone; Mg
2+, Cd
2+ and 
Zn
2+ yielded larger (5-8 nm) spherical oligomers; and Co
2+ and Ca
2+ produced ring oligomers 
with diameters between 70-90 nm for the former and 22-30 nm in the case of the latter [103]. 
It has been observed that the earliest form of α-syn protofibrils appeared to be mainly 
spherical [35]. The incubation of spherical α-syn oligomers with brain-derived membranes 
has been shown to produce pore-like ring-type protofibrils [103], which may disturb ionic 
gradients in cells. This conjecture was supported by showing that α-syn oligomers (and not Int. J. Mol. Sci. 2009, 10                 
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monomeric or filamentous α-syn) enhanced the membrane permeability for Ca
2+, an 
important subcellular messenger in liposomes [104]. The role for membrane permeabilization 
by α-syn in vivo is not clear and a large number of pores could lead to cell lysis, but even a 
subtle ionic disturbance could lead to neuronal dysfunction, death and degeneration.  
(7)  Insoluble aggregates: finally, α-syn have been shown to assemble into large, insoluble 
aggregates with two distinct morphologies (amorphous aggregates and fibrils), with a high 
amount of β-sheet structure. 
Because of this number of possible structural conformations, it seems reasonable to suggest that α-
syn is potentially prone to misfold [105]. Fibrillization is a nucleation polymerization process, in 
which there is an initial lag phase, during which nuclei are formed, followed by the exponential growth 
of the fibrils, and an equilibrium phase between the protein in solution and the protein in fibrillar form 
[49]. The fibrillization rate increases with higher α-syn concentration, low pH, high temperature, 
oxidative stress-inducing compounds such as DA [106], the dopaminergic neurotoxin 1-methyl-4-
phenyl-1,2,3,6-tetrapyridine (MPTP) [107], lipids [54] and pesticides [99]. The insoluble aggregates 
might represent the major building blocks of synucleinopathies-related inclusions, as LBs, LNs, GCIs 
and axonal spheroids, all of them observed in PD and related pathologies, as well as in other CNS 
disorders, including AD. 
 
3.2. Factors affecting α-syn fibrillization 
 
As stated above, a number of environmental and genetic factors can induce partial folding of α-syn, 
and therefore these same factors are able to accelerate the fibrillization process. Other aggregation-
prone factors are: 
(1)  Oxidation: the exposure of α-syn to oxidative agents induces the formation of high-order 
oligomers [74], and both the familial Parkininsonian A30P and A53T mutants have shown an 
even higher rate of self-assembly [108], providing support for the hypothesis that an 
impairment of cellular antioxidative mechanisms and/or overproduction of reactive oxygen 
species (ROS) may cause the initiation and progression of neurodegenerative 
synucleinopathies [109]. However, all amino acids are susceptible to oxidation [110], 
methionine being one of the easiest to undergo oxidation to form methionine sulfoxide 
(MetO). Thus, contrary to expectations, under mild oxidative conditions, when all four Met in 
α-syn are oxidized to MetO, the oxidized α-syn was found to be more unfolded than the non-
oxidized form and less prone to oligomerize and fibrillate. Indeed, it even proved able to 
inhibit the fibrillization of non-modified α-syn [111].  
DA metabolism in nigrostratial neurons can produce ROS and contribute to lipid 
peroxidation, DNA damage, impairment of mitochondrial function, depletion of reduced 
glutathione (GSH), and, finally, cell death [112]. Over-expression of α-syn, and especially its 
mutant forms, enhances the vulnerability of neurons to DA-induced cell death through 
massive generation of ROS [113]. It has been proved that conjugation of DA with α-syn 
impedes the protofibril-to-fiber transition and, therefore, potentially more cytotoxic 
protofibrils may accumulate [114]. Transfection of wt- α-syn, A30P or A53T mutants has Int. J. Mol. Sci. 2009, 10                 
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been reported to trigger apoptosis of cultured dopaminergic neurons, whereas there was an 
increase in survival of non-dopaminergic neurons [65]. Inhibition of DA synthesis by 
blocking TH activity prevented α-syn induced apoptosis. 
Damage caused by DA species is mediated by DA auto-oxidation catalyzed by free metals 
(especially Fe) [115], yielding 6-hydroxydopamine (6-OHDA) or through enzymatic 
deamination by MAOs to form toxic DA metabolites and hydrogen peroxide (H2O2) [116]. 
Levels of MAO-B appear to be highest in the substantia nigra. H2O2 produced as a by-
product of DA oxidation and as normal oxygen reduction by MAOs is highly permeable and 
cannot be converted to water by GSH peroxidase due the low level of available GSH as a 
reducer [117], allowing H2O2 to potentially diffuses out of dopaminergic neurons and damage 
the neighbouring neurons. Under normal conditions, ROS are kept under control by an 
efficient antioxidant cascade. This includes the cytosolic copper-zinc superoxide dismutase 
and the mitochondrial manganese superoxide dismutase, which convert superoxide to oxygen 
and H2O2. The latter, in turn, is removed by catalases and peroxidases. These enzymes are key 
to scavenge ROS generated by oxidative insults. For example, in a transgenic murine model 
that overexpressed Cu/Zn superoxide dismutase or GSH peroxidase and was treated with 
pesticide paraquat, which causes a PD-like profile, the transgenic animals did not show 
alterations as reductions in locomotor
  activity, levels of striatal DA and metabolites, or 
dopaminergic
 neurons in the substantia nigra, unlike non-transgenic controls in which all of 
these were affected [118]. 
Soluble α-syn is able to interact with the DA transporter (DAT) through the NAC domain 
[119], decreasing the amount of DAT in the PM, to allow for an optimal moderate level of 
synaptic DA reuptake to be accumulated into vesicles. In the event of α-syn aggregation, a 
decrease in the level of soluble α-syn results, and leads to the increased PM accumulation of 
DAT, giving rise to a massive entry of DA into the cell and consequent potential generation 
of ROS [116]. In accordance, the much more neurotoxic A53T mutant (but not A30P) 
interacts very weakly with DAT and causes an impairment of vesicular DA storage and 
release [119].  
Interestingly, the dopaminergic neurotoxin MPTP, which causes a PD-like 
neurodegeneration in rodents, humans and primates, enters into the cell through the DAT as 
its ionic metabolite MPP
+. It then targets the mitochondria, inhibits complex I of the electron 
transport chain, impairs ATP production, induces a loss of mitochondrial membrane potential 
allowing the release of cytochrome c and generation of ROS, and additionally, increases α-
syn mRNA and protein levels. The A53T mutant can enhance the vulnerability of cells to 
MPP
+, while α-syn null-mice are resistant to MPP
+-induced degeneration [120], signifying a 
fundamental role of α-syn in drug-mediated neurotoxicity. 
(2)  Interactions with polyanions: different glycosaminoglycans (GAGs) are involved in the 
formation of amyloid plaques in a variety of neurological disorders [121] and some highly 
sulphated GAGs (heparin and heparan-sulphate) as well as the proteoglycan agrin are able to 
bind to α-syn and stimulate its fibrillization in vitro. Furthermore, agrin and α-syn co-localize 
in LBs and LNs [122,123]. Int. J. Mol. Sci. 2009, 10                 
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(3) Interaction  with  polycations: polycations, such as polyamines, are cellular stabilizers of 
nucleic acids and membranes, and are essential for growth and differentiation. Interaction 
with α-syn induced the partial folding of α-syn and, consequently, its oligomerization and 
fibrillization [124] by binding to the negatively charged C-terminus. 
(4)  Interaction with histones: some animal models of PD are created by administration of the 
pesticide paraquat to mice where it elevates mouse brain α-syn levels [125]. Additionally, 
paraquat promoted in vitro the overexpression and translocation of α-syn into the cell nucleus, 
where it can interact with highly basic histones to form complexes that trigger its aggregation, 
and may reflect aspects of the in vivo situation [124]. 
(5)  α-Syn--α-syn crosslinking: tissue transglutaminase (tTG) catalyzes covalent crosslinking 
between reactive Lys and Glu residues [126]. Substrates for tTG include Aβ, tau (another 
hallmark of AD) and the NAC fragment of α-syn, all of them are proteins that undergo 
aggregation in several neurodegenerative disorders. tTG catalyzes α-syn cross-linking, 
leading to the formation of high molecular weight aggregates in vitro [127], mainly associated 
with the membrane fraction. Increased levels of tTG have been reported in the substantia 
nigra of PD postmortem brains [128]. 
(6)  Interaction with membranes: interaction with synaptic vesicles is one of the biological 
functions of α-syn. The membrane-bound fraction (about a 15% of total), was shown to have 
a high aggregation propensity and was able to seed aggregation of the cytosolic form of α-syn 
[55]. Furthermore, fatty acids and anionic lipids are potent inducers of α-syn fibrillization. In 
vitro association of soluble α-syn with lipid bilayers resulted in the formation of amorphous 
aggregates and filaments [129]. 
(7)  Interaction with other proteins: several proteins have been found to interact with α-syn and 
some of them were shown to stimulate α-syn aggregation in vitro, including tau [130], brain-
specific protein p25α [131], MAP-1B [132] and tubulin [133], all of which are components of 
LBs and/or GCIs, leading to cytoskeleton impairment. The mechanism of interaction remains 
unknown, but all contain basic motifs, suggesting that interaction could be through ionic 
bonds. On the other hand, transcriptional factors, such as NF-κB or Elk-1, have been found in 
LBs [134], suggesting that the sequestration of these factors in the cytosol may compromise 
the coordination of gene expression in degenerating cells. Similarly, high mobility group B-1 
protein (HMGB-1), which is a nuclear DNA-binding protein that facilitates the interaction 
between DNA and transcriptional factors, has been demonstrated to bind directly with 
filamentous α-syn in vitro and it too is present in LBs [135], potentially disturbing gene 
expression. α-syn also interacts with other important signalling proteins, epitomized by PKC 
or ERKs, which can affect cellular viability. 
(8) Proteins  inhibiting  α-synuclein aggregation: 
i.  Chaperones: heat shock proteins (HSPs) are a family of chaperones induced by stress 
conditions. These proteins suppress protein aggregation and participate in refolding and/or 
degradation. Hsp70 and Hsp40 are components of LBs and/or GCIs and co-localize with α-
syn. Overexpression of HSPs is able to suppress α-syn aggregation in vitro [136]. 
ii.  β- and γ-synucleins: these proteins share some features with α-syn, but lack others. The α- 
and β-syn have a conserved C-terminus; however β-syn is deficient of 11 aa within the Int. J. Mol. Sci. 2009, 10                 
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NAC region [137]. On the other hand, γ-syn lacks the Tyr rich C-terminal. All the three 
behave as typical natively unfolded proteins, but there is a little structural variability. β-syn 
has properties of a typical random coil, whereas α- and γ-syn are slightly more compact 
and structured [138]. Both are able to form fibrils, while β-syn is not, when incubated 
under the same conditions, however even β-syn can be forced to fibrillate in the presence 
of specific metals (Zn
2+, Pb
2+, Cu
2+), pesticides [139] or by addition of GAGs. 
Interestingly, the addition of β- or γ-syn in a 1:1 ratio with α-syn increased the time 
duration of the lag phase and decreased the elongation phase of α-syn fibrillization [138], 
and was completely inhibited at a 4:1 ratio of an excess of β- or γ-syn over α-syn. This 
suggests that β- and γ-syn may be regulators of α-syn fibrillization in vivo [140], 
potentially acting as chaperones. 
(9)  Phosphorylation: as discussed above, α-syn undergoes extensive phosphorylation at Ser-129 
in synucleinopathies and in ageing brains [141] and it is mostly unphosphorylated under 
normal conditions [71]. The specific phosphorylation at Ser-129 by CK2 resulted in 
oligomerization and fibrillization. Furthermore, oxidative stress has been described to 
enhance α-syn phosphorylation [72]. 
(10) Ubiquitin proteasome system (UPS) malfunction: mutated, misfolded or unassembled 
proteins are ubiquitinated to be degraded. There is evidence that UPS is impaired in several 
neurodegenerative diseases, including PD. For example, proteosomal subunits and 
ubiquitinated proteins have been found in LBs [142]. An inhibitory effect of α-syn aggregates 
on the hydrolytic activity of the 26S proteosome subunit in vitro has been reported [143], and 
a direct interaction between filaments and the 20S subunit has been shown. Accordingly, in 
transgenic animals, the inhibition of 20/26 S proteasome in substantia nigra led to α-syn 
accumulation and inclusion body formation, and resulted in a relatively selective degeneration 
of dopaminergic neurons [144]. Hsp70 expression can attenuate α-syn aggregation toxicity, 
by binding to α-syn filaments, abrogating its proteasomal inhibitory effect [145]. 
(11)  Effect of A30P, A53T and E46K mutations: all these three mutants have been shown to 
accelerate  α-syn oligomerization. While A53T and E46K increase fibril formation more 
rapidly than wt-α-syn and do not alter lipid-vesicle binding, suggesting that enhanced 
polymerization induces the disease in patients harbouring these mutations [129]. On the other 
hand, it has been reported that A30P fibrillates slowly, retarding significantly the formation of 
mature fibrils [35] and binds poorly to vesicles compared with the wt, maybe hindering 
axonal transport, leading to accumulation and aggregation, and accelerating the initial 
oligomerization of α-syn. 
(12)  C-terminal truncation: C-terminal truncated α-syn can increase α-syn-induced toxicity and 
aggregation ratio. Additionally, co-expression of full-length α-syn and the C-truncated form 
induced the formation of cytoplasmic inclusions and increased the susceptibility of cells to 
oxidative stress. This suggests that the C-terminus can play a role of an intramolecular 
chaperone by preventing α-syn from fibrillization [62]. Interstingly, C-terminally truncated 
A53T α-syn has been shown to induce the aggregation of full-length A53T protein faster than 
its wt counterpart, demonstrating that the mutation increases the accelerating effect that the 
truncated protein has on the aggregation of full-length α-syn [146]. Int. J. Mol. Sci. 2009, 10                 
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(13)  Interaction with metals: postmortem analysis of brain tissues from patients with PD confirm 
the presence of considerable amounts of metals, such as Fe, Zn and Al, in the substantia nigra 
as well as in LBs when compared with healthy age-matched controls [147,148]. α-syn can 
interact with several polycations, including Fe
2+, Al
3+, Zn
2+, Cu
2+, Mg
2+ and Ca
2+ [149], 
through the C-terminal domain, and this binding can catalyze protein aggregation. 
Additionally, some metals, such as Al [150], can induce a conformational change of α-syn 
from an unstructured to partially folded β-sheet structure intermediates and, lately, to fibrils 
[98]. Moreover, there is a shift in the Fe
2+/Fe
3+ ratio in favour of Fe
3+, and a significant 
increase in the Fe
3+-binding protein ferritin, together with a decrease in GSH content. 
Nevertheless, the concentration of metals necessary to induce aggregation is controversial. In 
general, the required concentration above the physiological values of the metals [151]. Hence, 
it is probable that metal-induced aggregation is carried out by oxidation of redox metals, 
rather than specific binding [152].  
As mentioned above, oxidation can lead to degeneration of dopaminergic neurons, resulting from 
the increased level of redox-active metals ions (Cu or Fe) within the substantia nigra, which initiates a 
cascade of events, such as α-syn oligomerization, mitochondrial dysfunction, cytotoxicity, and a rise of 
cytosolic free Ca, leading to cell death.  
 
3.3. Overexpression of α-synuclein 
 
As commented above, duplication or triplication of the α-syn gene has been reported in early-onset 
PD patients, suggesting a dose-dependence association with the disease, and genetic polymorphisms in 
the α-syn gene are linked to idiopathic PD by increases in α-syn concentration [40]. Other studies have 
revealed that the overexpression of α-syn can induce Fe-dependent aggregation [153].  
Under physiological conditions, there is an equilibrium between the natively unfolded and the 
partially folded conformation; therefore a high α-syn concentration may increase the rate of 
fibrillization due to an increased total concentration of the partially folded fibrillization-prone 
conformation [105]. Several studies report an increase in α-syn mRNA levels in brains of patients with 
PD compared to healthy controls [154]. In fact, overexpression of α-syn can generate α-syn 
immunopositive inclusions, together with alterations in mitochondria, increases in ROS production 
[155], lysosomal dysfunction [156] and Golgi fragmentation [157], leading to cell death. Of note, all 
these effects could be partially attenuated by antioxidants [155]. 
Accordingly, murine models transfected with recombinant viruses that overexpressed wt- α-syn or 
the A53T mutated form showed the typical features of PD in humans, including a loss of dopaminergic 
neurons in substantia nigra, α-syn inclusions similar to LBs [158] and a reduction in TH levels. In fact, 
a correlation between the number of α-syn immunoreactive LBs and α-syn mRNA levels has been 
found [159]. 
Another useful murine model to study PD is created by the injection of MPTP, which has been 
reported to enhance the production of α-syn at both mRNA and protein levels, and induce formation of 
α-syn-positive inclusions in neurons and abnormal locomotor function [160]. Similarly, administration 
of the pesticide paraquat to mice caused an upregulation of α-syn and formation of α-syn aggregates. A Int. J. Mol. Sci. 2009, 10                 
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faster PD-like model has been obtained by using an alternative pesticide, rotenone, which is highly 
lipophilic and readily crosses plasma membranes to allow rapid brain entry [161]. Within brain, it 
inhibits mitochondrial complex I and increases oxidative stress by ROS production leading to 
degeneration of dopaminergic neurons and fibrillar α-syn inclusions [162]. It has been demonstrated 
that at a nM range concentration, α-syn provides neurons protection against serum deprivation, 
oxidative stress and excitotoxicity, whereas in the μM range, cytotoxicity results [163]. Thus it is clear 
that there is a strong correlation between α-syn levels and aggregation-derivated toxicity. 
 
3.4. Role of oxidative damage induced by Fe in PD 
 
Both enzymatic and non-enzymatic catabolism of DA are accelerated by the presence of redox 
elements [164]. In particular, the high concentration of Fe in substantia nigra may catalyze the 
conversion of H2O2, produced during breakdown of DA, to highly reactive hydroxyl radicals by the 
Fenton reaction, resulting in oxidative damage [165]. In contrast, the superoxide radical is unreactive, 
but can serve as reducing agent for oxidized metal ions to produce more hydroxyl radicals from H2O2, 
via a cycle known as the Haber-Weiss reaction [166]. Oxidative stress may enhance Fe levels by 
deattachment from ferritin (see below), from heme proteins like haemoglobin and cytochrome c by 
peroxides and from iron-sulfur proteins by ONOO
.- [117]. Iron also catalyzes the conversion of an 
excess of DA to neuromelanin, an insoluble black-brown pigment that accumulates in all aged 
dopaminergic neurons. Neuromelanin sequesters redox ions with high affinity for Fe
3+; however, when 
bound to an excess of Fe
3+, neuromelanin tends to become pro-oxidant, reducing Fe
3+ to Fe
2+, which is 
released from neuromelanin and increase the amount of iron available to react with H2O2 [167]. 
In cells, the main route of Fe uptake is through the transferrin receptor (TfR) at the cell surface. 
Each TfR binds to a Fe-laden transferrin (Tf) molecule and internalizes it via endocytosis. The acidic 
pH of endosomes causes the dissociation and unloading of Fe from Tf, and is then recycled back to the 
cell surface. In cytoplasm, most available Fe is sequestered by the iron-storage protein ferritin and a 
small amount is left free. In the case of Fe deficiency, the levels of TfR in the plasma membrane are 
increased and ferritin synthesis is downregulated, enhancing the availability of free Fe. When there is 
too much free Fe, TfR levels are downregulated and ferritin synthesis becomes upregulated. 
This homeostasis is regulated at the translational level by two cytoplasmic iron regulatory proteins 
(IRPs), IRP1 and IRP2 [168; 169], based on their coordinately binding to iron-response elements 
(IREs) within the 5’-untranslated region (5-UTR) of mRNA ferritin and to the 3-UTR of mRNA TfR. 
When cellular Fe levels are low, IRPs bind to the ferritin 5-UTR, resulting in a block of ferritin 
translation and bind to the TfR 3-UTR, stabilizing the mRNA TfR and preventing its endonuclease 
cleavage [117]. Therefore, there is a decrease in Fe storage, an increase in extracellular import and 
consequently, an enhancement in cytoplasmic Fe levels. In the presence of excess Fe, IRP2 is degraded 
[170] and IRP1 inactivated, thereby increasing ferritin levels. 
There are several lines of evidence that support the contention that Fe accumulation in a number of 
degenerative disorders may be a primary event, rather than a consequence of the disease: 
(1)  Injection of Fe3Cl into the substantia nigra of rats has been reported to result in a selective 
decrease of striatal DA, which supports the assumption that Fe initiates dopaminergic Int. J. Mol. Sci. 2009, 10                 
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neurodegeneration in PD. This decrease was prevented by infusion of the Fe chelator, 
desferrioxiamine [171]. 
(2)  Neurodegeneration by 6-OHDA is selective for catecholamine neurons, and it is rapidly oxidized 
to yield cytotoxic catecholaminergic semiquinones and quinones with production of H2O2 and 
hydroxyl radicals. Iron-deficient rats are resistant to 6-OHDA neurotoxicity, suggesting that Fe 
could be a trigger [172]. Moreover, 6-OHDA-induced toxicity has been reversed by the Fe 
chelator, desferal [173]. These studies indicate that an enhancement of Fe concentration in 
substantia nigra may be upstream in neurodegenerative process associated with PD. 
(3)  By using MPTP injection in monkeys, a number of Fe chelators have been shown to attenuate 
MPTP oxidative toxicity, suggesting that Fe mediates or accentuates MPTP effects [174]. 
(4)  Targeted deletion of the gene encoding IRP2 in mice causes a misregulation of Fe metabolism 
and neurodegeneration, leading to abnormal brain Fe deposition, ataxia, bradykinesia and 
tremors [175]. 
(5)  Mutation in the gene that codifies for a ferritin subunit, resulted in disease similar to PD, termed 
neuroferritinopathy, which is characterized by Fe deposits, progressive neurodegeneration and 
axonal cyst formation with neurofilaments, ubiquitin and tau protein at the periphery, all of them 
components of LBs [176]. 
(6)  Polymorphisms in five genes related to Fe homeostasis (Tf, TfR,  frataxin, lactoferrin and 
haemochromatosis-related protein gene) have been linked to sporadic PD incidence, suggesting 
that there are variations in proteins involved in Fe metabolism that contribute to PD   
pathogenesis [177]. 
Anther link between Fe and oxidative stress comes from the discovery of upregulation of ferritin 
and downregulation of TfR in response to conditions of heightened oxidative stress, leading to IRP 
inactivation [178], and inversely, overexpression of ferritin decreased the oxidative levels [179]. 
However, there are reports where increases of H2O2 level enhanced the activation of IRPs [180]. In a 
study, when the Fe concentration was increased, IRP2 activity disminished, as expected, but IRP1 
activity decreased in the beginning and later aberrantly enhanced, indicating the presence of complex 
feedback loops to mitigate Fe-induced oxidative damage [181]. Another study assessed that there was 
neither increase in ferritin levels under excess of Fe nor alteration in the IRP-IRE system in PD brains, 
maybe induced by the sequestering of Fe by α-syn [182]. 
Another example of IRP-IRE mediated regulation is the regulation of mRNA levels of 
mitochondrial complex I, which is compromised in PD [183]. The mitochondrial electron transport 
chain is the major source of free radicals in vivo, therefore dysfunction of IRP regulation of complex I 
or IRE-containing tricarboxilic acid cycle enzymes, that provide substrates for the electron transport 
chain, would impair mitochondrial function and would lead to exacerbated levels of oxidative stress. 
Also, an IRE motif has been located in the 5-UTR of murine and human erythroid-specific delta-
aminolevulinic acid synthase (eALAS) mRNA which encodes the first, and possibly rate limiting, 
enzyme of the heme biosynthetic pathway [184], and for which translation is controlled by IRPs. 
Fe-oxidative stress has also been shown in several studies to promote α-syn aggregation [153], 
maybe due to alterations in secondary structure leading to partially folded states, more susceptible to 
oligomerization [98]. Fe has been identified as a component of LBs [185], showing the tight Int. J. Mol. Sci. 2009, 10                 
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relationship among Fe, oxidative stress, α-syn and PD. Indeed, in accordance with and adding to the 
described literature, an IRE has recently been discovered within the 5-UTR of the α-syn mRNA [186]. 
 
4. Protein-binding Control Sequences within the 5-UTR of the Alpha Synuclein Transcript 
 
RNA-protein interactions play a key role in many fundamental biological processes through their 
effects on RNA splicing (in the case of the α-syn mRNA, see ref [187]), turnover, post-transcriptional 
processing such as capping or poly(A) addition [188], transport, localization and translation [189]. 
RNA binding of regulatory proteins can modulate synthesis of multiple proteins or differential 
expression from one mRNA, not only by alternative splicing (such is the case of α-syn), but also by the 
choice of a certain translation initiation codon [190]. In mammals, translation repression by sequence-
specific RNA-binding proteins through the 5-UTR can be robust [191]. Another important regulatory 
element is sited at the 3’-end of the mRNA (3-UTR). This is the poly(A) tail, characteristic of all 
mRNAs, which can upregulate or downregulate translation depending on its length and the binding of 
certain regulatory proteins [188]. 
The best studied example of a small structural element within the 5-UTR that affects the translation 
of eukaryotic mRNAs is a stem-loop of around 30 nt, termed the iron-responsive element (IRE), whose 
role on Fe homeostasis has already been described. The IRE RNA stem loop is usually located within 
50 nt from the 5’ cap site of a given mRNA, and this distance is functionally important, because 
ribosomal preinitiation complex binds to this region. Iron-regulatory proteins (IRPs) are the 
modulators of translation of the downstream cistron through their binding to the IRE. Our laboratory 
recently identified a fully functional IRE within the 5-UTRs of mRNAs implicated in 
neurodegenerative diseases, such as that of the amyloid-precursor protein (APP), associated with AD 
[192]. This APP IRE was found to be related to those found within 5-UTRs of the mammalian TfR and 
ferritin L- and H-chain mRNAs, conferring Fe-dependent regulation. Screening for drugs that interact 
with the 5-UTR of APP mRNA has led to the discovery of a number of metal chelators that suppress 
holo APP translation [193,194], and likely represent the mechanism via which specific experimental 
AD drugs lower amyloid- peptide levels through lowering APP translation [195,196]. 
As Figure 2 shows, the recent finding of a putative IRE within the 5’-UTR of α-syn mRNA [186], 
as encoded by exons 1 and 2, is highly significant. Indeed, two different splicing sites, producing 
different 5-UTRs have been found by Xia, et al. 2001 [187], thus generating one transcript encoding 
the IRE loop consensus sequence 5’CAGUGU3’ across the splice site junction where, interestingly, 
the longer transcript encodes the same loop region across its splice junction (Figure 2). The putative α-
syn IRE provides a possible mechanism through which Fe can carry out its deleterious action by 
regulating in some way α-syn expression. In fact, our preliminary data show that the α-syn IRE from 
the shorter α-syn transcript, indeed, confers desferrioxamine-dependent repression of a luciferase 
reporter gene in response to iron chelation in SH-SY5Y neuroblastoma cell lines, whereas this 
sequences has not yet been tested for the longer α-syn alternatively spliced transcript   
(unpublished data). 
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Figure 2. An RNA Stem loop is predicted within 5' Untranslated region (5’UTR) of the 
Parkinson’s disease alpha synuclein (α-syn) transcript that is homologous to the Iron-
responsive element (IRE) in H-ferritin mRNA.  
 
Panel A: The α-syn 5’UTR is encoded by exon-1 and exon-2 of the α-syn gene, which can be 
alternatively spliced to generate either a shorter exon-1/-2 transcript (Panel B upper transcript, 
[187]), or the alternatively spliced transcript (longer by 375 bases, Panel B lower transcript). Panel 
B: The alternatively spliced α-syn 5’UTR mRNAs. There is a predominant transcript that encodes a 
CAGUGU motif at the exon-1/exon-2 splice junction. Also present is the longer alternatively 
spliced α-syn mRNA variant (Lower transcript) that encodes exon-1 and exon-2 but includes 375 
bases of sequences from intron-1. Panel C: Alignment of the α-syn 5’UTR from human, mouse and 
rat demonstrating the lack of an IRE homology in rodent IREs (in bold is the CAGUGN loop 
sequences of canonical IREs). Similar to the boxed alignment of the α-syn 5’CAGUGU3’ motif 
against the IREs of ferritin H- and L- chains (iron storage), ferroportin (iron transport), erythroid 
eALAS (heme synthesis) mRNAs [186]. Panel D: This α-syn 5’UTR stem loop (ΔG =53 kcal/mol) 
was predicted by the RNA/FOLD computer program. This α-syn stem loop resembles the classical 
IRE RNA stem loop (5'CAGUGN3' loop motif) that controls iron-dependent L- & H-ferritin 
translation & transferrin receptor (TfR) mRNA stability. 
 
Providing more support for a role of α-syn in iron metabolism, a recent finding showed that α-syn 
and the heme metabolism genes erythroid-specific 5-aminolevulinate-synthase gene (ALAS2), 
ferrochelatase (FECH), and biliverdin-IX beta reductase gene (BLVRB) form a block of tightly 
correlated gene expression co-induced by the transcription factor GATA-1 which is able to noticeably 
enhance α-syn expression [197]. (Ferrochelatase catalyzes the chelation of iron into protoporphyrin, a 
precursor of heme group; biliverdin-IX beta reductase gene converts bilirubin from biliverdin, ALAS2 Int. J. Mol. Sci. 2009, 10                 
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is a key enzyme in heme anabolism). The GATA family of transcription factors, which contain Zn 
fingers in their DNA binding domains, have emerged as candidate regulators of gene expression in 
hematopoietic cells.  GATA-1 is a hemopoietic transcription factor that specifically occupies a 
conserved region within α-syn intron 1, where several polymorphisms linked to PD have been detected 
[38]. Endogenous GATA-2 is highly expressed in substantia nigra vulnerable to PD, also occupies 
intron 1, and modulates α-syn expression in dopaminergic cells [197]. 
Interestingly, β- and γ-syn transcripts lack this IRE. This finding suggests that the potential IRP1/-2 
binding capacity of α-syn 5-UTR evolved after the divergence of these evolutionally related genes. 
Interestingly, the human α-syn IRE maintains the CAGUGU loop region motif that is typical of the 
canonical IRE stem loop, whereas rodents lack it (Figure 2C). This suggests that the capacity of the α-
syn IRE to potentially bind IRP1 and/or IRP2 is unique to human α-syn and evolved after the 
divergence of humans from rodents on the evolutionary timeline. 
 
5. Conclusions 
 
In PD, α-syn aggregation is the typical hallmark, and it has been demonstrated that MPTP-induction 
and α-syn overexpression triggers Fe-mediated α-syn oligomerization, because Fe chelation reduced 
the toxicity exerted by MPTP. It is known that certain neurotoxins, such as 6-OHDA, are selective for 
dopaminergic neurons, and cause a PD-like clinical profile and, meaningfully, this neurotoxicity only 
can be exerted through Fe mediation, since again Fe chelation was able to revert this effect. 
The presence of an IRE within the 5-UTR of the α-syn gene and the importance of α-syn in PD, 
clearly indicates a role for Fe in the pathogenesis of the disorder. Thus, α-syn levels are critical to hold 
Fe homeostasis, and an impairment in the IRE-mediated regulation system of α-syn can lead to 
overexpression, to a misfunction in regulation of Fe storage, and consequently to Fe-mediated 
oxidative stress, α-syn aggregation, dopaminergic neuronal death, DA depletion, and finally to PD 
symptoms. Indeed, the oxidative insult is not limited to these neurons in substantia nigra, and can 
expand to other areas of the brain leading to massive neuronal death. For this reason, it is frequent to 
find dementia in patients affected by PD. 
Duplication or triplication of the α-syn gene leads to α-syn overexpression and aggregation, perhaps 
by altering the equilibrium between IRE-containing α-syn and IRE-containing Fe regulatory protein 
system with regard to the recruitment of IRPs, although even a subtle change in α-syn concentration 
could have the same effect. A shift in α-syn isoform ratio towards the 112 aa isoform, that is more 
prone to aggregate than the full-length protein, also could occur in vivo.  
Synucleinopathies are additionally related to AD, since neurofibrillary tangles of protein tau, a 
hallmark of AD, are in many cases found co-localized with LBs [198]. Moreover, APP mRNA also 
encodes an IRE, revealing the critical importance of Fe homeostasis in neurodegenerative processes 
and the main role of the IRE translational regulatory system in the CNS.  
In conclusion, the search for new therapeutic agents for PD able to regulate increasing α-syn levels 
by binding to its IRE might retard Fe-induced neurotoxicity, as well as avoid the deleterious effects of 
α-syn overproduction and aggregation. Ever since the first-line of treatment of PD, with L-dopa that 
was developed 50 years ago, there has been no other drug that has proved to be sufficiently efficacious 
to substitute for it, despite its side effects and short duration of efficacy. Hence, in the future these Int. J. Mol. Sci. 2009, 10                 
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potential new translation blocker drugs could widen the available clinical options for PD treatment by 
providing the opportunity for arresting and/or reversing the progression of not only this disease but 
also other related neurodegenerative synucleinopathies. 
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